GH
EquityGuardant Health, Inc.
Health Care · Diagnostics & Research
$93.90
+93.90 (+0.00%)
Open
N/A
Day Range
$92.09 - $96.99
52W Range
$34.88 - $120.74
Volume
2M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Guardant Health (GH) Gained from Better-Than-Expected Results
Guardant Health acquires MetaSight amid positive 2026 financial outlook
Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know
Guardant Health Expands Cancer Testing Platform With MetaSight Deal And Shield Growth
Guardant buys MetaSight for $59M upfront to acquire blood test tech
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| 001540.KQ | AHN-GOOK PHA | $8,070.00 | N/A | 5.45% | +0.00% |
| ABBV | AbbVie Inc. | $232.06 | N/A | 2.87% | +0.00% |
| LLY | Eli Lilly and Company | $1,052.20 | N/A | 0.59% | +0.00% |
| NVO | Novo Nordisk A/S | $37.46 | N/A | 4.49% | +0.00% |
| EJG.F | EBOS Group Ltd. R | $11.70 | N/A | 5.14% | +0.00% |
| 5889.T | JAPAN EYEWEAR HOLDINGS CO LTD | $1,998.00 | N/A | 4.20% | +0.00% |
| 0332.KL | TOPVISN | $0.17 | N/A | 11.76% | +0.00% |
| ABT | Abbott Laboratories | $116.32 | N/A | 2.06% | +0.00% |
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Palo Alto, California.
guardanthealth.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for GH
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for GH.